Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;10(8):FM01-2.
doi: 10.7860/JCDR/2016/19052.8286. Epub 2016 Aug 1.

Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis

Sankalp Yadav  1 , Gautam Rawal  2 , Mudit Baxi  3
Affiliations

Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis

Sankalp Yadav et al. J Clin Diagn Res. 2016 Aug.

Abstract

The developing countries are having an abruptly growing number of drug resistant tuberculosis cases. Multidrug-resistant tuberculosis (MDR-TB) is a type of TB in which the strain of Mycobacterium tuberculosis is resistant to at least Isoniazid and Rifampicin, the two most effective of the four first-line TB drugs (the other two drugs being Ethambutol and Pyrazinamide). The management of such cases is complex and requires a treatment for 24-27 months. The current guidelines available for the management of this type of TB are largely based on the second line TB drugs which are relatively costly, less efficacious and are associated with greater side-effects. The introduction of newer drugs to cater to the high mortality and early sputum culture conversion in the MDR-TB cases is an absolute essential. In the present article, the authors discuss about the introduction of a newer drug named Bedaquiline for the control of MDR-TB.

Keywords: ATP Synthase; Diarylquinoline; Drug-resistance.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yadav S. A new concept in tuberculosis awareness in the low income countries. Edorium J Tuberc. 2015;5:1–4.
    1. Yadav S, Rawal G. Tubercular nodular episcleritis- A case report. J Clin Diagn Res. 2015;9(8):ND01–02. - PMC - PubMed
    1. Yadav S, Rawal G. Primary extrapulmonary multidrug-resistant tuberculosis of the sternum without HIV infection. J Clin Diagn Res. 2016;10(1):RD01–03. - PMC - PubMed
    1. Fox GJ, Menzies D. A review of the evidence for using Bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther. 2013;2(2):123–44. - PMC - PubMed
    1. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300. - PMC - PubMed

LinkOut - more resources